Other Events ·
Sagimet Biosciences Inc. updated its investor presentation on July 20, 2026, highlighting clinical progress for its…
SGMTSagimet Biosciences Inc.
Sagimet Biosciences Inc. updated its investor presentation on July 20, 2026, highlighting clinical progress for its lead molecule, denifanstat. The company reported that denifanstat met all primary and secondary endpoints in a Phase 3 clinical trial for moderate to severe acne in China, where the NDA was accepted by the NMPA in December 2025. Sagimet plans to initiate a US-based Phase 3 clinical trial for denifanstat in the second half of 2026. Additionally, the company's follow-on FASN inhibitor, TVB-3567, began a Phase 1 clinical trial in June 2025. As of March 31, 2026, the company held $104.5 million in cash. Sagimet is a biotechnology company developing novel therapeutics for metabolic and dermatological diseases.